

Anglo-French Drugs & Industries Ltd

Unlisted Share Financial Report

Company Overview

Anglo-French Drugs & Industries is a pharmaceutical manufacturer with a product portfolio spanning APIs, formulations, and OTC medicines for domestic and export markets.

Market Snapshot

CURRENT PRICE / SHARE Rs 1,609.01	MARKET CAP 181.82 Cr	P/E RATIO 0.00	P/B RATIO 0.00
BOOK VALUE / SHARE Rs 1,195.84	FACE VALUE Rs 10	DEBT TO EQUITY 0.15	RETURN ON EQUITY 12%
TOTAL SHARES 11,30,000			

Prices are indicative over-the-counter levels as of 07 July 2026. Actual deal prices may vary.

Corporate Details

CIN	L24230KA1923PLC010205
PAN	AAACA9756E
Registrar (RTA)	Canbank Computer Services
Sector	Healthcare
Industry	Pharmaceuticals

Income Statement (Rs Crore)

Particulars	2023	2024	2025
Revenue	103	95	88
Cost of Material Consumed	68	70	68
Change in Inventory	9.5	-2	-0.5
Gross Margins	24.76%	28.42%	23.3%
Employee Benefit Expenses	23	19	18
Other Expenses	43	19	19
EBITDA	-40.5	-11	-16.5
OPM	-39.32%	-11.58%	-18.75%
Other Income	299	5	30
Finance Cost	3	2	2
Depreciation & Amortisation	3.3	3	3
EBIT	-43.8	-14	-19.5
EBIT Margins	-42.52%	-14.74%	-22.16%
Profit Before Tax	251	-12	8
PBT Margins	243.69%	-12.63%	9.09%
Tax	60	0	0
Profit After Tax	191	-12	8
Net Profit Margin	185.44%	-12.63%	9.09%
EPS	Rs 1,480.62	Rs -97.56	Rs 70.8

Balance Sheet - Assets (Rs Crore)

Particulars	2023	2024	2025
Fixed Assets	13	16	22
Capital Work in Progress	0	0	0
Investments	0.2	0.5	0.4
Trade Receivables	59	42	32
Inventory	9	12	11.5
Other Assets	191.8	149.5	126.1
Total Assets	273	220	192

Balance Sheet - Liabilities (Rs Crore)

Particulars	2023	2024	2025
Share Capital	1.29	1.23	1.13
Face Value	Rs 10	Rs 10	Rs 10
Reserves	207	170	124
Borrowings	26	9	19
Trade Payables	19	21	28
Other Liabilities	19.71	18.77	19.87
Total Liabilities	273	220	192

Cash Flow Statement (Rs Crore)

Particulars	2023	2024	2025
Profit Before Tax	251	-12	8
Operating Profit Before Working Capital	253	-11	-16
Change in Receivables	-25	17	10
Change in Inventories	24	-3	0.1
Change in Payables	-3	1.5	8
Other Changes	-4	-5.56	0.9
Working Capital Change	-8	9.94	19
Cash Generated From Operations	245	-1.06	3
Tax	-60	1	-1
Cash Flow From Operations	185	-0.06	2
Purchase of PPE	-3	-4	-9
Sale of PPE	0	1	0.2
Cash Flow From Investment	-170	41	45
Borrowing	-9	-17	-10
Dividend	0	-2.5	-0.19
Equity	0	-22.5	-53
Others From Financing	-3	-5	17.19
Cash Flow from Financing	-12	-47	-46
Net Cash Generated	3	-6.06	1
Cash at the Start	0.2	3	0.09
Cash at the End	3.2	-3.06	1.09

Key Ratios

Particulars	2023	2024	2025
Operating Profit Margin	-39.32%	-11.58%	-18.75%
Net Profit Margin	185.44%	-12.63%	9.09%
Earning Per Share (Diluted)	Rs 1,480.62	Rs -97.56	Rs 70.8

Source: Compiled by Neoma Capital research. Data as of FY2025. Figures may be restated in subsequent filings.